RTW Institute launches to push patient-centered health policy

RTW Institute launched Sept. 14 in New York as a nonprofit focused on medical innovation, regulatory predictability and access to new medicines. The group opened with a UN Headquarters event and plans research, policy analysis and stakeholder engagement aimed at shaping U.S. health policy.

Why it matters: - RTW Institute is entering a crowded health-policy landscape with a stated focus on making drug development more predictable and patient access more reliable. - The launch comes as scientific progress is moving faster than the systems that regulate, finance and deliver new medicines. - The Institute says its work is designed to translate policy complexity into practical recommendations for policymakers, patient communities and the public.

What happened: - RTW Institute announced its formal launch on Sept. 14, 2026, in New York City as a nonprofit health policy organization. - The launch was marked by an event at United Nations Headquarters in New York. - The event brought together leaders from government, patient advocacy, medicine, research and the life sciences. - RTW Institute said it will focus on health policy, medical innovation, regulatory predictability and access to life-changing medicines. - The Institute said it is dedicated to strengthening the systems that turn scientific discovery into accessible medicines.

The details: - RTW Institute plans to use original research, policy analysis, stakeholder engagement and public education. - The organization aims to develop evidence-based recommendations that improve regulatory predictability and support a resilient medical innovation ecosystem. - RTW Institute also plans to expand patient access to important new treatments. - Initial priorities include strengthening regulatory consistency and predictability. - The Institute also wants to advance sustainable approaches to financing medical innovation. - Another priority is addressing barriers that could delay or limit patient access. - Since forming in January 2026, RTW Institute has engaged with federal policymakers, patient advocacy organizations and life sciences leaders. - RTW Institute is a founding member of the Rare Disease Innovation Coalition, formerly the Rare Disease Advocacy, Biotechnology, and Investor Coalition. - The coalition brings together rare disease advocates, biotechnology executives and investors. - The coalition aims to promote a more consistent, predictable and patient-centered regulatory environment. - Early meetings included senior officials at the U.S. Department of Health and Human Services and the U.S. Department of the Treasury. - Those meetings focused on regulatory modernization, sustainable innovation and patient access. - RTW Institute published Innovation Is the Best Medicine: A Policy Roadmap for Biotechnology. - The report examines how U.S. drug development must evolve to keep pace with global competitors. - The report also traces the policy dynamics behind America’s healthcare affordability crisis. - RTW Institute is led by founding CEO Kinnari Patel, PharmD, MBA. - Patel is described by the Institute as a life sciences executive, drug developer and rare disease advocate with more than two decades of experience. - Patel’s background includes work across 25 therapeutic programs in multiple disease areas and senior leadership in gene therapy. - Patel also founded the global Light Up for Rare campaign. - The campaign aims to increase awareness of people living with rare diseases. - More information is available on RTW Institute’s website.

Between the lines: - RTW Institute is positioning itself as a bridge between scientific innovation and the policy process that determines whether patients benefit from new treatments. - The emphasis on regulatory predictability suggests the group sees uncertainty in the approval and access system as a major bottleneck. - The coalition work signals an effort to build cross-sector influence rather than operate as a narrow advocacy group. - The Institute’s focus on affordability alongside innovation reflects a broader policy argument: the two goals can be aligned rather than treated as tradeoffs.

What's next: - RTW Institute said it will continue research and engagement grounded in data, real-world experience and the perspectives of patients and families. - The organization plans to convene stakeholders with different views on health policy to find common ground. - RTW Institute expects to translate those discussions into actionable policy solutions. - The Institute will keep working across medical innovation, health policy and patient outcomes as a 501(c)(3) nonprofit within the RTW Investments, LP group in a research and policy capacity.

The bottom line: - RTW Institute is betting that patient-centered policy can make medical innovation both faster and more accessible without sacrificing predictability or sustainability.